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Acid fast bacilli (AFB) sputum microscopy is used to diagnose tuberculosis (TB) and to
evaluate the effectiveness of anti-tuberculosis drugs in TB eradication program. The AFB
sputum microscopy should be performed before treatment, two months after intensive phase
and four months after advance phase treatment. The aim of this study was to evaluate the
sputum conversion rate of AFB in pulmonary TB patients who received category I of antituberculosis (anti-TB) drugs. Evaluation of sputum conversion was perfomed before initation
of anti TB drugs and at the end of the intensive phase. This cohort prospective study was done
from February to May, 2018. Nine pulmonary TB patients fulfilled the criteria during the study.
This AFB sputum microscopy was evaluated by using Ziehl Neelsen and read by means of
International Union Against Tuberculosis and Lung Disease (IUATLD) scale. Nine sputum
smear positive were followed for two months. After two months (end of the intensive phase),
the smear conversion rate was 100%. All patients received standard dose of anti-TB drugs in fix
dose combination (FDC). It can be concluded that the sputum conversion of AFP in pulmonary
TB patients who received category I of anti-TB was success at the second month of intensive
phase.
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INTRODUCTION
Tuberculosis is still serious problem of infectious disease
all over the world (WHO, 2011). Data from Riskesdas,
2018, showed that the prevalence of pulmonary TB
was 0.4%, not different from 2007. The prevalence of
pulmonary TB in East Java is 0.2, with the prevalence
of cough more than 2 weeks is 5.0 and bloody sputum
is 2.4 (Kemenkes RI, 2013). In Indonesia, there is an
estimated one TB case among three cases that have not
been observed by the TB program (Kemenkes RI, 2015).
Cases of pulmonary TB in East Java has increased each
year. Of the 38 districs in East Java in 2015, Surabaya
has the highest number of pulmonary TB with the
number of patients reaching 4,028 in 2014. Based on
this number, there were 2,000 new TB cases, and the
rest are TB patients who have not recovered since 2010.
Based on data from the City Health Office of Surabaya
in 2016, it was known that the indicator of success rate
in 2015 was 79.21%, whereas standard national indicator
for success rate is more than 85%. The result showed
that the success rate in Surabaya in 2015 has not met the
national target.
Adequate treatment of pulmonary TB is very important
to reduce morbidity, mortality, and to prevent the spread
of TB (Singla R, et al, 2007). Transmission of TB can
be controlled by good findings and curing. Findings
and curing are based on the results of examination of

the patient’s sputum, therefore examination of sputum
with direct microscopic acid-fast bacilli (AFB) becomes
fundamental. Similarly, the examination of the level of
positivity of BTA at the beginning of the examination
is due the level of positivity is also useful for assessing
the degree of infectious disease. Sputum smear-positive
tuberculosis patients are the most significant source of
infection because droplet from the sputum carry TB
bacilli (CDC, 2015). The sputum conversion rate or
SCR in TB patients is the percentage of smear positive
pulmonary that converted to smear negative after two
months of the intensive phase. WHO recommends to
use sputum conversion rate for monitoring TB control
programs, and as a tool for assessment in TB patients
with still positive smears (WHO, 2010).
Under Indonesian Health Ministry for national
programme for Tuberculosis, sputum conversion rate
(SCR) at the end of two months of intensive phase is
an important indicator, which is ideally expected to be
at least 80% (Kemenkes RI, 2014). When the smear
sputum is negative, the patients are no longer a source
of infectious (ATS, 2005). Patients who fail sputum
conversion, especially at the end of the intensive phase
have a poor clinical outcome (Kuaban C et al, 2009 ;
Dembele SM et al, 2007). If the sputum results are
still negative at the end of the second month, then the
intensive phase is extended for one month.
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The objective of this study was to assess the sputum smear
conversion rate and to analyze the correlation between
the initial smear grading and the failure treatment among
new cases of smear-positive pulmonary TB receiving
category I anti TB drugs in intensive phase.
METHODS
Study Design
This two months cohort prospective, was conducted at
Sidotopo Wetan Primary Health Care Centre, Surabaya.
The diagnosis criteria for pulmonary TB in this study
were at least two positive sputum smears test results..
All new smear positive naive or newly-diagnosed
pulmonary TB outpatients were enrolled from February
to May, 2018. For each TB patients, sputum smear was
done by Ziehl-Neelsen stain to confirm the diagnosis
of pulmonary TB and to exclude a drug resistant TB.
Acid fast baccilli (AFB) or smear sputum were postive
if appears red-colored bacteria, fine rods, sometimes
granules, accompanied by other non-smear bacteria and
blue-colored leucocytes.
The sampling technique in this study was non random
sampling with purposive sampling technique. The
researchers determines the sampling by specific
characteristics that are in accordance with the objectives
of the study, so that it is expected to answer the research
problems Inclusion criteria in this study as follows:
newly diagnosed smear positive pulmonary tuberculosis
category I or started first-line antituberculosis treatment,
aged 17-60 years old. Exclusion criteria were extra
pulmonary TB, TB patients with comorbid disease
(diabetes mellitus, liver disease, autoimun history),
pregnancy, lactation, pneumonia, and patients with HIV.
All patients were followed up for 2 months after initiation
of TB therapy. The drop out criteria were death during
two months of study, inability for collecting sputum, and
transfer to the hospital or any other institutions.
The smear grading based on International Union Against
Tuberculosis and Lung Disease (IUATLD) scale, as
folows: negative (smear contains no AFB in 100 fields),
1+ (10-99 AFB in 100 fields), 2+ (1-9 AFB/field in
at least 50 fields), and 3+ (>10 AFB/field in at least
20 fields). Inclusion criteria in this study as follows :
newly diagnosed smear positive pulmonary tuberculosis
category I or started first-line antituberculosis treatment,
aged 17-60 years old. Exclusion criteria were extra
pulmonary TB, TB patients with comorbid disease
(diabetes mellitus, liver disease, autoimun history),
pregnancy, lactation, pneumonia, and patients with HIV.
The drop out criteria were death during two months of
study, inability for collecting sputum, and transfer to the
hospital or any other institutions.
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Before study participation, patients were asked for
demographic information (sex, age, comorbid diseases),
clinical symptoms and signs of pulmonary TB, and
smoking habits were obtained from medical record. At
least three sputum of each TB patients (spot-morningspot) are collected over 2 consecutive days, spot sample
when patients suspected of TB, one morning sample
for tomorrow, and one spot sample on the second day.
Sputum smear examination in this study was done at
begining (before initiation of TB treatment) and at the
end of 2nd month. One of the smear results shows a
positive results, the patient is diagnosed TB.
TB Treatment
All new pulmonary TB patients received FDC in
intensive phase based on their weight, to assure the
right dose for two months. Each FDC contains four
drug regimens (isoniazid, rifampicin, pyrazinamide,
and ethambutol). The dosage of TB drugs was modified
or adjusted when severe adverse effects of TB drugs
occured. The adherence of taking medicines is monitored
by the supervisior of “Pengawas Menelan Obat (PMO)”
or Directly Observed Treatment Shortcourse (DOTS),
represented by the patient’s family. Everytime the patient
comes to the TB unit, the patiens will be asked about the
amount of medication that has been taken or swallowen.
Data Collection and Analysis
The study mainly involved the primary data from the
result of sputum smear of pulmonary TB patients. The
secondary data was used to assess the demographic data
and history of illness and medical of each patients. The
term sputum-positive cases were the pulmonary TB
patients who convert to sputum negative at the end of
2nd months or at the end of intensive phase. The term
sputum negative cases were the pulmonary TB patients
who still sputum negative at the end of 2nd months after
TB treatment.
The Saphiro Wilk test was used to assess the normality
of the variables. The study results were presented as
mean with standard deviation (SD) and as percentage.
Chi-square and paired t-test was performed to evaluate
differences before and after treatment of two months TB
drugs. The data were analyzed by statistical software
SPSS 15.0. Statistical significance was accepted when
P value <0.05.
RESULTS
Nine sputum positive pulmonary TB patients were
initiated on treatment. All patients completed the
2 months of intensive phase. The demographic
characteristic is shown in Table 1. One patient had initial
high sputum-grade (3+). By Chi-Square analysis, there
is no significant relationship between sex and grade of

Pharm Sci Res, Vol 6 No 3, 2019

Evaluation of Category I of Anti-tuberculosis Therapy

185

Table 1. Demographic characteristics of TB Patients
Sputum smear positive patients (n=9)
Mean age (years)
Body Weight (Kg)
Sex

46.1±10.5
48.0±6.5

Male
Female
Comorbid

6
3

Without comorbid
8
With comorbid
1
Initial sputum grade before initiation
of TB drugs
0, n (%)
1, n (%)
2, n (%)
3, n (%)

0 (0%)
4 (44.4%)
4 (44.4%)
1 (11.2%)

Table 2. Sputum smear before and after TB treatment
No. of Patients
1
2
3
4
5
6
7
8
9

Sputum smear before the
treatment
1+
1+
2+
2+
1+
2+
2+
1+
3+

smear-positive (p = 0,06) at the beginning of the study.
It means, sex had no correlation with grade of smearpositive. The smear examination before and after of TB
treatment is shown in Table 2.
For calculating the sputum conversion rate, the number
of smear positive who had smear negative at the end
of intensive phase is divided by the number of smearpositive patients before TB treatment and the ratio
is multiplied by 100. In this study of 9 smear positive
pulmonary tuberculosis case, 100% patients at the end
of 2nd month were smear negative. Number of FDC daily
for each patients based on body weight was shown in
Table 3. Seven patients (77.7%) had minor side effects
or adverse effects. All adverse effects observed during
this study was shown in Table 4. No patients lead to
final termination of TB standard therapy due to adverse
effects. Major adverse effects such as hepatoxicity,

Sputum smear after the
treatment
-

P Value

<0.001

jaundice, ototoxicity, and psychiatric changes were not
observed during this study. No patients had history of
smoking (ever smokers or ex-smokers).
Table 3. Daily dose of Fixed-Dose Combination
(FDC) based on body weight
No. of Patients Body Weight No of FDC
(Kg)
tablets daily
1
42
3
2
53
3
3
42
3
4
38
3
5
54
3
6
60
4
7
46
3
8
47
3
9
50
3
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Table 4. Adverse effect occured during anti-TB drugs
Type of ADRs

Number (%)

Total patients
Total ADRs cases

7 (77.7)
11
2 (18)
2 (18)
3 (27)
4 (37)

Nausea & Vomiting
GI Upset
Flu-like syndrome
Arthralgia
DISCUSSION

Sputum conversion, from smear positive to negative
is one of the most important outcomes in pulmonary
TB, besides clinical outcome. Because it ilustrates
the infection control in TB patients. In this study, TB
was diagnosed based on symptoms, clinical signs and
confirmed by sputum smear examination. No patient
was confirmed by sputum culture and chest x-ray.
Several studies shown that nonconversion at the end of
the intensive phase is one of the strongest predictors for
TB therapy failure, although it is not the best indicator
because of its weak predictive value (Kuaban et al, 2009).
Based on Table 1, subjects suffering from tuberculosis
tended to be more male than female, 6 men dan 3
women. This is similar to the data of Riskesdas, 2013,
showed that the prevalance of pulmonary TB incidence
greater in men. The incidence of pulmonary TB tend to
be more in male, because it associated with different
social interaction between men and women, smoking,
and alcohol causes a decrease of immune system, so
that when the body exposed to TB bacilli, it can cause
symptoms and if tested become positive pulmonary TB
(Kemenkes RI, 2013). Our study is also similar to the
study by Shanmuganathan et al, who showed that the
majority of TB patients were male. It could be indicated
that sex is a risk factor for TB (Shanmuganathan et al,
2015). Sex steroid hormone in woman, estradiol, could
activate macrophage, and natural killer cells from female
mice could produce more interferon-gamma (IFN-γ)
than that of cells from male mice (Callippe et al., 2008).
In this study, 9 sputum positive pulmonary tuberculosis
(category I) patients become smear negative at the end of
2 months of intensive phase or 100% sputum conversion
rate. Based on age, our study was not similar with several
studies for smear sputum conversion. A study by Yellapa
et al, showed that the mean age associated with sputum
non-conversion at the end of two months of treatment
was 45,2 ± 15,3 years (Yellapa et al., 2016). It similar
with a study conducted in South India reporting that
age more than 45 years is associated with poor sputum
conversion rate of 60% (Rekha et al., 2007). Study by
Babalik et al showed that smear conversion decreased at
age more than 40 years due to decreased immunity. The
important immune response in pulmonary tuberculosis
E-ISSN 2477-0612
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is macrophages and T cells. Macrophages are useful for
fagocytes of Mycobacterium tuberculosis and introduce
antigens resulting from phagocytosis to T cells. T cells
will secrete IFN-γ. IFN-γ will stimulate macrophage to be
more effective to phagocyte Mycobacterium tuberculosis
(Babalik et al., 2012).
The successfull conversion rate in this study might be
because all patients had no history of smoking and miliary
TB. Study by Boer et al, showed that tobacco smoking
was found to prolonged or even delay culture conversion
during TB treatment in pulmonary tuberculosis patients.
The study was also showed that TB patients who current
smokers had higher risk of non conversion after TB
therapy for two months compared to ex-smokers or
never smokers (Boer et al., 2013). Smoking causes
several effects on the respiratory system, including
affects immunological responses, decreased clearance
of inhaled bacteria or viruses. Smoking also inhibits the
immunity of anti-TB T-helper type 1 (Th-1) by inhibiting
the activation of innate immune and recruitment of lungT-cell (Shaler CR et al., 2013). Smoke cause disrupted
ciliary function in the respiratory tract, so it can increase
the risk of TB (Caetano Mota et al., 2012). Another
study by Bouti et al, showed the different results. The
relationship between factors like age, sex, weight,
smoking and delays of conversion of positive sputum
smears after two months of treatment had no statistically
significant association (Bouti et al., 2013).
In our study, the administration of anti TB drugs or FDC
doses was divided according to the weight, in which
patients with 30-37 Kg received 2 FDC, 38-54 Kg
received 3 FDC, 55-70 Kg received 4 FDC and more than
70 Kg received 5 FDC as shown in Table 3 (Kemenkes
RI, 2011). This is in accordance with the dosage given
to our patients. There were no overdose or underdose.
All TB patients are classified into the right dose. Study
by Al-Shaer et al, showed that pulmonary TB patients
who received FDC, the sputum smear conversion was
significantly greater compared to separate tablet of TB
drugs (FDC 36.6 ± 19.5 days vs. separate tablet 56.1 ±
28.8 days) with P value 0.008. It was also showed that
FDC was significantly greater among TB patients with
pretreatment of bacilliary load of TB 3+ (Al-Shaer et
al., 2018). The usual or standard for TB therapy regimen
is a 2 months regimen, including isoniazid, rifampicin,
pyrazinamide, and ethambutol, and then followed by a
4 months regimen of isoniazid and rifampicin. All drugs
regimen are available as separate tablets or capsules.
Another regimen of TB drugs is fix dose combination
or FDC. It means, in one tablet, includes four drug TB
drugs. The FDC is easy to arrange dose calculation,
prevent errors of prescribing, increase adherence and
decrease of pill dumping (Blomberg B et al., 2003).
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Some factors have been identified that may prolong
of smear conversion. These include high sputum
smear acid fast bacilli (AFB) grade, cavitatory lesion,
untreated hyperglycaemia or diabetes mellitus, older
age, treatment with less than four anti TB drugs (Long
et al., 2003). Another result from this study indicate
that the side effects of anti-TB drugs is still serious
problems during TB treatment in intensive phase. A
total of 11 cases of side effects from 9 patients were
observed during this study. The highest percentage was
arthralgia (37%). Arthralgia is strongly suspected to be
caused by pyrazinamide. One of the minor side effects
of pyrazinamide is arthralgia. In non-gouty TB patients
who received pyrazinamide, hyperuricemia commonly
leads to arthralgia. The mechanism is associated with
the main metabolit of pyrazinamide, pyrazinoic acid,
which inhibits the elimination of uric acid due to
inhibition of renal tubular secretion. It suggested that
the administration of pyrazinamide be discontinued
or dose adjusted. Sometimes, the hyperuricemia is
typically asymptomatic, and administration of aspirin
or nonsteroidal anti-inflammatory drugs help to reduce
pain (Gholami K et al., 2006). However, our patients
were not measured for uric acid levels to be associated
with athralgia. The second most side effects of antiTB drugs in this study was flu-like syndrome. Flu–like
syndrome is rare and usually occurs in TB patients who
use intermitten TB regimens that include rifampicin. A
study by Gulbay et al, showed that the incidence of flulike syndrome in hospitalized TB patients was observed
in 3 cases, 2 of them the administration of rifampicin
was discontinued. The result also showed that the
interval between the initation of rifampicin therapy and
flu-like syndrome was 11.6 days (7-21 days) (Gulbay et
al., 2006).
One patient suffered Morbus Hansen (Leprosy). Leprosy
is a chronic infection caused by Mycobacteria leprae,
which attack the peripheral nerves, skin and other organs.
In patient who are experiencing TB treatment and also
leprosy, there is an interaction between rifampicin and
dapson. Rifampicin increases dapsone excretion, in the
process of the dapsone metabolic pathway, it involves the
hydroxylation of one amino group by cytochrome 3A4 to
form hydroxylamine dapsone. Rifampicin also increases
levels of hydroxylamine (metabolite of dapsones) in the
blood (Baxter, 2009). In this case, dapsone doses may
need to be increased, but this can increase the potential
exposure to toxic hydroxylamine metabolites which can
cause methemoglobinemia.
Additionally, the limitation of our study is the small
sample size. The results may not represent the entire
populations or generalized because of a limited number
of samples. Besides that, the confounding variabels,
such as nutrition and body weight in the second month
was not evaluated.
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CONCLUSION
In conclusion, our study showed a succesfully smear
conversion at the end of 2nd month of anti-TB drugs
used. More prospective studies about sputum conversion
and also larger sample are needed to confirm our results.
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